24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500

Medical Disorders
Basic InformationLookupsLatest News
U.S. Coronavirus Cases Near 3 Million as Hospitals in Sun Belt Fill Up With PatientsAHA News: Months After Infection, Many COVID-19 Patients Can't Shake IllnessCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityMajor Medical Groups Urge Americans to Wear Face MasksBlack Patients Fare Worse After AngioplastyHow Immune System Fights COVID-19 May Be Key to Vaccine SuccessWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?New U.S. Coronavirus Cases Hit Another HighMultiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July ChallengesStroke Appears 8 Times More Likely With COVID Than With FluCOVID-19 Death Risk Twice as High in New York City as Some CountriesFireworks Are Bad News for Your LungsScientists Find Source of COVID ClotsNew U.S. Coronavirus Cases Top 50,000 as More States Slow Reopening PlansNumbers of Non-COVID-19 Deaths Up During PandemicNo Good Evidence on Accuracy of Coronavirus Antibody Tests: StudyAHA News: COVID-19 Pandemic Brings New Concerns About Excessive DrinkingMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Trauma of Racism Fuels High Blood Pressure Among Black Americans: StudyCOVID-19 Blood Test Might Predict Who Will Need a VentilatorWhat's the Best DIY Face Mask Against COVID-19?Deep Brain Stimulation May Slow Parkinson's, Study FindsU.S. Could See 100,000 New Cases of COVID-19 Each Day, Fauci SaysGlobally, COVID-19 Cases May Stretch Far Beyond Official Numbers: StudyFBI: Beware of Scammers Selling Fake COVID-19 Antibody TestsAHA News: Sadness and Isolation of Pandemic Can Make Coping With Grief HarderVaping-Related Lung Injuries Still Happening -- And May Look Like COVID-19Most With Coronavirus Not Sure How They Caught It: CDCDon't Get Sick While Swimming This SummerAmid Pandemic, Too Many Americans Are Hesitating to Call 911Mask Up! Don't Let Down Your Guard Against COVID-19Wildfire Smoke Causes Rapid Damage to Your Health: StudyCOVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysIntestinal Illness Spurs Recall of Bagged Salads Sold at Walmart, AldiCOVID Threatens the 3 out of 4 Americans Who Can't Work From HomeHispanic Americans Being Hit Hard By COVID-19Global Coronavirus Cases Pass 10 Million as U.S. Struggles With Surge in InfectionsStarted Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: StudyIs 'Pooled' Coronavirus Testing the Next Step for America?U.S. Coronavirus Task Force Warns of Rising Case Numbers, Especially Among YoungWho's at Highest Risk From COVID-19? CDC Updates Its ListStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsPromising Results Mean Coronavirus Vaccine Trial Could Start by AugustWhen Can Sports Fans Safely Fill Stadiums Again?Coronavirus Baby Boom? Survey Says Maybe NotCOVID-19 Typically Mild for Babies: Study
Questions and AnswersLinks
Related Topics


In Early Trial, an Ancient Drug Shows Promise Against Severe COVID-19

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Jun 24th 2020

new article illustration

WEDNESDAY, June 24, 2020 (HealthDay News) -- There's new evidence that a 2,000-year-old medicine might offer hope against a modern scourge: COVID-19.

The medication, called colchicine, is an anti-inflammatory taken as a pill. It's long been prescribed for gout, a form of arthritis, and its history goes back centuries. The drug was first sourced from the autumn crocus flower.

Doctors also sometimes use colchicine to treat pericarditis, where the sac around the heart becomes inflamed.

Now, a team of Greek researchers reporting Wednesday in JAMA Network Open said their small trial suggests colchicine may indeed help curb severe COVID-19.

The trial involved 105 Greek patients hospitalized in April with COVID-19. Besides receiving standard antibiotics and antivirals (but not remdesivir), half of the participants got daily doses of colchicine for up to three weeks, while the other half did not.

The results "suggest a significant clinical benefit from colchicine in patients hospitalized with COVID-19," according to the team led by Dr. Spyridon Deftereos, a cardiologist at Attikon Hospital in Attiki, Greece.

Specifically, while the condition of seven of 50 patients who didn't get colchicine "clinically deteriorated" to a severe stage (for example, requiring mechanical ventilation to survive), this was true for just one of the 55 patients who did receive colchicine, the researchers said.

Writing in a journal editorial, a group of U.S. physicians agreed that the study has limits, but applauded the Greek team for "showing us that an old drug may still have new life."

Dr. Amir Rabbani, a cardiologist at the University of California, Los Angeles, and colleagues stressed in the editorial that the study size was too small to offer a definitive statement on whether colchicine should be used routinely against COVID-19.

But they said that its effects on certain blood markers of heart function -- as observed in the new study -- suggest that colchicine has anti-inflammatory and anti-clotting effects that could help limit the cardiovascular damage wreaked by COVID-19.

Larger trial needed -- and it's on the way

Dr. Rajiv Bahl is an emergency medicine physician in Orlando, Fla., who's seen the ravages of severe COVID-19 in patients firsthand. Reading over the Greek findings, he noted that colchicine "has also been used to prevent heart conditions such as pericarditis and other inflammatory conditions affecting the body."

Still, the new study is too small, so although it "does show some early promise, future studies need to be conducted before we can incorporate colchicine as an extensively used medication to help combat COVID-19," Bahl said.

That trial is already underway.

As first reported in April, researchers in the United States and Canada are testing colchicine's ability to keep high-risk COVID-19 patients from getting sick enough to land in the hospital.

According to researcher Dr. Priscilla Hsue, a professor of medicine at the University of California, San Francisco (UCSF), "one of the unique aspects is that we're trying to hit this before people need to be hospitalized."

Colchicine is the medication of choice for a few reasons, Hsue explained: Unlike many drugs being tested in hospital patients -- which are given by infusion or injection -- colchicine tablets are easy to take and inexpensive, so it could easily be used at home. The medication also has a long history of safe use for gout, she added.

Beyond that, Hsue added, a recent trial found that low-dose colchicine benefits people who've recently suffered a heart attack. Patients who took one tablet a day curbed their risk of further heart complications or stroke over the next two years.

Heart injury is a common problem in people who become seriously ill with COVID-19 -- at least partly, researchers suspect, because of a runaway immune system reaction called a "cytokine storm."

Unique design

Hsue believes it's worth investigating whether colchicine could help prevent such heart issues.

The North American trial aims to enroll 6,000 patients newly diagnosed with COVID-19 who are at increased risk of serious illness -- because they are older than 69, or have conditions like heart or lung disease.

To keep those patients isolated at home, the study has an unusual "contactless" design: Patients will receive the medication by courier, and have follow-up visits via video or phone. The researchers will look at whether the tactic lowers hospitalization rates and deaths over one month.

Dr. Randy Cron is a professor of pediatrics and medicine at the University of Alabama at Birmingham, and an expert on the "cytokine storm."

While Cron believes that targeting cytokine storms in COVID-19 is wise, he had some reservations about giving colchicine to people with no signs of the severe immune reaction. Could any dampening of their immune response against the virus backfire?

"My concern is, could it make the infection worse?" Cron said.

Hsue, however, pointed to the safety record of the medication, and noted that the dose given in the trial will be lower than what's routinely used for gout.

In the end, experts say the only way to definitively prove any medication works for COVID-19 is through clinical trials.

The colchicine study is currently recruiting patients, with UCSF and New York University School of Medicine being the first two U.S. sites involved.

More information

The World Health Organization has updates on COVID-19.